Anavex Life Sciences Corp (AVXL)

[falconer66a]

EMA Knows, Will Be Supportive

I'm going to speculate the EMA has been watching Blarcamasine for some time now and this may even have played a role in their cool reaction to the 'mabs.

It is foolish to think that any and all of the world’s drug regulatory authorities, along with drug development researchers in the world’s big pharmaceuticals, are all ignorant of and utterly disinterested in Anavex Life Sciences Corp.

That’s not the way productive and innovative science researchers, in any field, operate. In a former position I was an advanced placement biology teacher, preparing talented and gifted high school science students for merit-based scholarships and admissions to science and medical curricula at top-line universities. Since then I’ve been involved in ecological research in a university research program, where, with state and federal grants awarded for the merit of my proposals my research team has solved important ecological problems. Like other research professionals, I keep searching for all that is happening in my fields of expertise.

Key is this. No one doing innovative science research — especially in medicine — ever fails to diligently stay current in everything that can be known regarding new approaches to the topics they are investigating. In the case of Anavex, they are proposing clever, innovative ways to treat and/or prevent major central nervous system (CNS) diseases. Any and all involved with finding CNS disease solutions need to examine and consider Anavex’s sigma-1 receptor agonist molecules.

So, yes, very clearly the people at the European Medicines Agency (EMA) have scrutinized the same data and reports we have on Anavex’s molecules. On the basis of what they’ve learned, they cannot in any way be reluctant to have Anavex move forward with all that will be required to attain approval of blarcamesine in Europe. Just the opposite, they will be very supportive. Let’s watch and see how this turns out in the EMA offices in Amsterdam.